Category
blog
-
2023
-
FDA Accepts sBLA for Pembrolizumab Plus Chemotherapy in Advanced Gastric/GEJ Adenocarcinoma
-
Regenxbio Gene Therapy Candidate Gets Fast Track Status for Duchenne Muscular Dystrophy
-
FDA rejects Eli Lilly’s mirikizumab for ulcerative colitis, citing manufacturing concerns
-
FDA grants breakthrough device status for Genetesis’ CardioFlux MCG
-
FDA Updates Safety Labeling and Prescribing Information for Opioid Pain Meds
-
Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307
-
Omega-3 fatty acids might reduce cognitive decline risk
-
GSK to acquire BELLUS for £1.6 billion
-
Big Pharmas finally strike with acquisitions, signaling accelerating pace of M&A
-
Agenus Rises on Fast Track Tag for Cancer Combo Drug